Theodore Halkias - Dec 30, 2021 Form 4 Insider Report for agilon health, inc. (AGL)

Role
Chief Business Officer
Signature
/s/ Lyn Amor Macaraeg, as Attorney-in-Fact
Stock symbol
AGL
Transactions as of
Dec 30, 2021
Transactions value $
-$352,330
Form type
4
Date filed
1/3/2022, 03:03 PM
Previous filing
Dec 28, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGL Common Stock Options Exercise $12.1K +12.1K +222.91% $1.00* 17.5K Dec 30, 2021 Direct F1
transaction AGL Common Stock Sale -$334K -12.1K -69.03% $27.54 5.43K Dec 30, 2021 Direct F1, F2, F3
transaction AGL Common Stock Options Exercise $1.16K +1.16K +21.38% $1.00* 6.6K Dec 31, 2021 Direct F1
transaction AGL Common Stock Sale -$32K -1.16K -17.62% $27.55 5.43K Dec 31, 2021 Direct F1, F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGL Options (Rights to Buy) Options Exercise $0 -12.1K -0.71% $0.00 1.7M Dec 30, 2021 Common Stock 12.1K $1.00 Direct F5
transaction AGL Options (Rights to Buy) Options Exercise $0 -1.16K -0.07% $0.00 1.7M Dec 31, 2021 Common Stock 1.16K $1.00 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes restricted stock units.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, which was adopted prior to September 7, 2021.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $27.50 to $27.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $27.50 to $27.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 These options were granted on April 27, 2017 and vested in four equal installments on May 15th of each of 2018, 2019, 2020, and 2021.